Navigation Links
Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
Date:10/26/2008

WASHINGTON, Oct. 26 /PRNewswire/ -- Sequoia Pharmaceuticals presented positive results today from two studies on SPI-256, a novel investigational HIV protease inhibitor (PI). One study based on an in vitro analysis demonstrates that the mode of interaction of SPI-256 with HIV protease provides a rationale for its high potency and high genetic barrier to resistance. The second study conducted in healthy volunteers demonstrates that SPI-256 is generally safe and well tolerated in humans and is amenable to boosting by pharmacokinetic enhancers (PKEs). The data were presented at the 48th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th annual Infectious Diseases Society of America (IDSA) joint meeting held in Washington, D.C.

"Two ongoing significant needs in contemporary HIV therapy are: new agents that have activity against mutant virus and also have a high genetic barrier to developing resistance; and new agents that can boost the pharmacokinetic levels of existing drugs," said Martin Markowitz, MD, professor and clinical director at the Aaron Diamond AIDS Research Center. "These data on SPI-256 look very promising and address the need for new agents with activity against protease inhibitor-resistant virus as well as the development of resistance. I look forward to further advancements and innovations in HIV that will address our needs in the treatment community from a resistance, as well as a PK, point of view."

Data on SPI-256 at this conference

Discovery and in vitro activity of SPI-256

Scientists from Sequoia Pharmaceuticals presented their structure-based approach that led to the development of SPI-256. Prior to discovering SPI-256, Sequoia scientists examined three-dimensional structures of wild-type and drug-resistant mutant HIV proteases bound to selected inhibitors. By analyzing these structures, the Sequoia scientists were able to identify a subset of main-chain and active-site atoms of
'/>"/>

SOURCE Sequoia Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 A study using ... offered a new look at the composition of carotid ... physicians understand and treat the disease, a leading cause ... Baptist Health Lexington between September 2010 and May 2012, ... Journal of the American College of Cardiology (JACC) ...
(Date:9/30/2014)... 30, 2014 The Chinese wound care market ... rise in the incidence of lifestyle diseases, coupled with ... affordability of better quality of wound care products provide ... coverage of public health insurance schemes and increased reimbursement ... Based on the findings of primary and secondary researches, ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
Breaking Medicine Technology:New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2China Wound Care Market 2China Wound Care Market 3Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... (Nasdaq: ARAY ), the premier radiation oncology ... present at the Oppenheimer Healthcare Conference in New York ... EST/10:00 a.m. PST.  A live webcast ... Investor Relations page of the Company,s website at ...
... Foundation for Infectious Diseases (NFID) joins the Centers for ... of influenza prevention during National Influenza Vaccination Week, December ... holiday season and beyond. Influenza vaccination rates ... years, but many parents remain unaware that annual vaccination ...
Cached Medicine Technology:National Foundation for Infectious Diseases Supports 2011 National Influenza Vaccination Week 2National Foundation for Infectious Diseases Supports 2011 National Influenza Vaccination Week 3National Foundation for Infectious Diseases Supports 2011 National Influenza Vaccination Week 4
(Date:9/30/2014)... Antonio, TX (PRWEB) September 30, 2014 ... September, the Editorial Board of Living with a ... that sheds light on hematological disorders as disabling conditions. ... SSA requires more than a diagnosis to establish a ... cell, chronic thrombocytomenia, myelofibrosis, hereditary telangiectasia, coagulation defects, polycythemia ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Catalent ... of advanced delivery technologies and development solutions for ... a full agenda for the 25th Annual CPhI ... from October 6th to 9th. , Catalent is ... capability expansions during the show, including its facilities ...
(Date:9/30/2014)... Jiwa Law Corporation, a personal injury law ... now be offering free consultation for personal injury claims of ... firm for the first time to meet the Vancouver ICBC ... opportunity to understand what their rights are. The experts at ... to explain to them what the law firm can do ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... its first “crowdfunding” campaign through GoFundMe. The campaign, which ... was for a portion of the funds necessary to ... bus for the Stockton Unified School District (SUSD). The ... will provide a portion of the funds necessary for ...
(Date:9/30/2014)... Coast Dental and Orthodontics is ... practice, located at 1010 Shaw Avenue in Clovis, CA. ... services , and specialty dental care including orthodontics, endodontics, ... and convenient dental care, our Clovis dentists also strive ... Coast Dental at 559-777-6113 to schedule an appointment. , ...
Breaking Medicine News(10 mins):Health News:Living with a Disability Magazine Marks National Sickle Cell Health Month with New Article on Hematological Disorders 2Health News:Living with a Disability Magazine Marks National Sickle Cell Health Month with New Article on Hematological Disorders 3Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 2Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 3Health News:Jiwa Law Corporation Now Offers Personal Injury Consultation Without Any Charge 2Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 2Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 3Health News:Coast Dental Clovis Celebrates Grand Opening 2Health News:Coast Dental Clovis Celebrates Grand Opening 3
... WHO has revealed that Africa's TB crisis has its origin ... of the two million people who die from TB every ... nurse at the African Medical and Research Foundation (AMREF) clinic ... who succumbed to TB were also infected with HIV. According ...
... study conducted by Columbia University Medical Center has ... in osteoarthritis, could be effective// in the treatment ... drug treatment with Cox-2 inhibitors or surgery was ... chronic shoulder pain. ,Approximately 1.5 million ...
... to World Health Organization (WHO), two fresh cases of ... from Mudug region//, in southern Somalia and northeastern Somalia ... to neighbouring countries. ,The cases also threaten ... the outbreak which has affected a total of 199 ...
... shoulder pain were left with only two options previously, either ... the safety concerns surrounding Vioxx and other Cox-2 inhibitors were ... has found that sodium hyaluronate, a drug approved by FDA ... for treating the shoulder pain. ,The study was ...
... Transesophageal echocardiography (TEE) is a recent progress in echocardiography ... procedure entails the insertion of a // probe into ... off the heart and help in enabling a motion ... echocardiogram. , ,These detailed images are capable of ...
... and Drug Administration (FDA) approved asthma Flovent HFA for kids ... a reformulation of Flovent that uses the more environmentally friendly ... the canister. ,It is an inhaled corticosteroid that ... , The medication initially was approved by the FDA ...
Cached Medicine News:Health News:Sodium Hyaluronate Shows Promise In Treatment Of Shoulder Pain 2Health News:New Drug For Treating Chronic Shoulder Pain 2Health News:New Drug For Treating Chronic Shoulder Pain 3
This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 20-200 microliter range....
... and density. Proven ergonomic design reduces hand fatigue, prevents injury. Dry seal ... 20-200 ... 1.0~2.0 Imprecision(%) ... 1 Dimensions: ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,411-9) or contact custom...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: